STOCK TITAN

Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Annexon, a clinical-stage biopharmaceutical company (Nasdaq: ANNX), announced that CEO Douglas Love will join the “Orphan CNS Panel” at the Cowen 42nd Annual Healthcare Conference on March 8, 2022, at 2:10 p.m. ET. The panel focuses on complement-mediated conditions affecting the CNS. A live webcast will be available on Annexon's Investors page and will remain archived for 30 days post-event. Annexon is pioneering complement-targeting medicines aimed at autoimmune and neurodegenerative disorders, with a pipeline that includes three clinical-stage drug candidates and various early-stage programs.

Loading...
Loading translation...
Argus Session date unavailable
-5.54% session move Open Argus
Details

News Market Reaction – ANNX

The recorded move for ANNX in the trading session of this news was -5.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders, today announced that Douglas Love, Esq., president and chief executive officer, will participate in a virtual panel titled, “Orphan CNS Panel,” during the Cowen 42nd Annual Healthcare Conference on Tuesday, March 8, 2022, at 2:10 p.m. ET.

A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon
Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its start, C1q, to bring therapies to patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company’s proprietary complement-targeting platform utilizes well-researched classical complement-mediated autoimmune and neurodegenerative processes triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a broad portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway, which may provide more complete protection against complement-mediated disorders of the body, brain and eye. The company’s pipeline includes three clinical-stage drug candidates, ANX005 (intravenous administration), ANX007 (intravitreal administration), and ANX009 (subcutaneous administration), as well as a robust early-stage pipeline of preclinical and discovery stage programs. Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio. For more information, visit www.annexonbio.com.

Investor Contact:

Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media Contact:

Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What event is Annexon participating in on March 8, 2022?

Annexon will participate in the Cowen 42nd Annual Healthcare Conference, specifically in the 'Orphan CNS Panel' at 2:10 p.m. ET.

Who will represent Annexon at the Cowen conference?

Douglas Love, the CEO of Annexon, will represent the company at the Cowen 42nd Annual Healthcare Conference.

How can I watch the live event from Annexon?

You can access the live webcast of the event on Annexon's Investors page under the 'Events & Presentations' section.

How long will the webcast of the Annexon event be available?

The webcast will be archived on Annexon's website for 30 days following the presentation.

What type of therapies is Annexon developing?

Annexon is developing a new class of complement-targeting medicines for autoimmune and neurodegenerative disorders.

What are the clinical-stage candidates in Annexon's pipeline?

Annexon's pipeline includes three clinical-stage drug candidates: ANX005, ANX007, and ANX009.

Keep reading